Answers are grounded in this paper and cite their sources.
Validates pTau181p cutoff for ruling out amyloid pathology in a diverse population, suggesting effectiveness in clinical practice.
This study validated a plasma tau phosphorylated at threonine 181 (pTau181p) cutoff using the Elecsys® Phospho-Tau (181P) assay (Roche Diagnostics) to rule out amyloid pathology in a diverse real-world cohort
No takes yet. Share an insight, caveat, or question.
Hortsch et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: